AUTHORS
Marie Luise Hütter-Krönke, MD, Mouad Abouqateb2, William Boreland3, Christophe Peczynski4, Rand Fatouh5, Francis Ayuketang Ayuk, MD6, Raynier Devillier, PhD7, Matthias Stelljes8, Linde Morsink9, Peter Von Dem Borne, MD, PhD10, Robert Zeiser, MD, PhD11, Thomas Schroeder, MD12, Gerald Wulf13, Johannes Schetelig14, Peter Dreger, Prof. Dr. med.15, Igor Wolfgang Blau, MD16, Henrik Sengeloev, MD17, Stephan Mielke18, Francesca Kinsella, PhD19, Jakob Passweg, MD, MS20, Wolfgang Bethge, MD21, Matthias Eder22, Eva Wagner Drouet23, Gesine Bug, MD24, Arnon Nagler I, MD25, Lars Bullinger, Prof. Dr. med.26, Ulrich Keller27, Stephan Bohl, MD28, Zinaida Peric29, Charlotte E. Graham30, Alberto Mussetti31, Lars Gjaerde, MD32, Ivan Moiseev, MD, PhD33, Olaf Penack, MD, PhD34
AFFILIATIONS
1 Charité – University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany
2 EBMT Paris Study Unit, Paris, France
3 Complications Working Party of the EBMT, Paris, France, EBMT Paris Study Unit, Paris, France
4 Complications Working Party of the EBMT, Paris, France, EBMT Paris Study Unit, Paris, France
5 Complications Working Party of the EBMT, Paris, France, EBMT Paris Study Unit, Paris, France
6 University Hospital Eppendorf, Hamburg, Germany
7 Programme de Transplantation e Therapie Cellulaire, Marseille, France
8 University Hospital Muenster, Muenster, Germany
9 University Medical Center Groningen, Groningen, Netherlands
10 University Leiden Medical Center, Leiden, Netherlands
11 University of Freiburg, Freiburg, Germany
12 University of Essen, Essen, Germany
13 University of Gottingen, Gottingen, Germany
14 University Medical Center Dresden, Dresden, Germany
15 University Hospital Heidelberg, Heidelberg, Germany
16 Charité – University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany
17 Rigshospitalet CopenhagenUniversity Hospital, Copenhagen, Denmark
18 Karolinska University Hospital, Stockholm, Sweden
19 Birmingham Centre for Cellular Therapy and Transplantation (BCCTT), Birmingham, United Kingdom
20 University Hospital Basel, Basel, Switzerland
21 Universität Tübingen, Tübingen, Germany
22 Hannover Medical School, Hannover, Germany
23 University Medical Center Mainz, Mainz, Germany
24 University Hospital Frankfurt, Goethe University, Frankfurt, Germany
25 Chaim Sheba Medical Center, Tel-Hashomer, Israel
26 Charité – University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany
27 Charité – University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany
28 Charité – University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany
29 Complications Working Party of the EBMT, Paris, France, Department of Hematology, Rijeka University Hospital Centre, Rijeka, Croatia
30 Complications Working Party of the EBMT, Paris, France, Comprehensive Cancer Center, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
31 Complications Working Party of the EBMT, Paris, France, Institut Catalá d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain
32 Complications Working Party of the EBMT, Paris, France, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
33 Complications Working Party of the EBMT, Paris, France, RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian Federation
34 Charité – University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, Complications Working Party of the EBMT, Paris, France
ABSTRACT
INTRODUCTION
The incidence of hematologic malignancies rises steeply with age, and for many of them allogeneic hematopoietic cell transplantation (allo-HCT) remains the only option for long-term survival. Advances in donor availability, supportive care, GVHD prophylaxis and reduced-intensity conditioning have progressively lowered non-relapse mortality (NRM), historically the main barrier to transplanting older patients. This decline in toxicity has continuously promoted allo-HCT in elderly patients. However, patient selection remains a main challenge. We therefore determined the NRM and factors influencing it in a population of >5000 patients aged 70 years or older from the European Blood and Marrow Transplantation (EBMT) registry.
METHODS
Patients aged 70 years or older at first allo-HCT for a hematologic malignancy, transplanted between July 2014 and June 2024 using peripheral blood (PB) or bone marrow grafts from any donor type, were included. The primary endpoint was NRM at 1 year. Secondary endpoints included 2-year NRM, relapse incidence (RI), overall survival (OS), and progression-free survival (PFS). To determine the impact of variables influencing outcome, multivariable Cox regression analyses were performed. Models were stratified by diagnosis and disease status and accounted for center effects.
RESULTS
In total, 5,469 patients were included; median age was 71.8 years (IQR 70.8-73.2; maximum 87.5) with 64.2% being male patients. Karnofsky Performance status (KPS) was 90-100% in 63% and <=80% in 37% of all patients. Main indications for allo-HCT were acute myeloid leukemia (AML) (55.0%), myelodysplastic syndrome (MDS) (22.4%) and myeloproliferative neoplasms (MPN)/MDS/MPN Overlaps (12.6%). At transplantation 69.2% of patients were in complete or partial remission and 30,9% had primary induction failure, active or stable disease. Donor types consisted of unrelated donors in 75%, haploidentical donors in 15.4% and matched related donors in 8.8%. Conditioning strategy was myeloablative (MAC) in 19.8% and reduced intensity (RIC) in 80.2%. GVHD prophylaxis included ATG in 54.8% and post-transplant cyclophosphamide in 20.9%. Median follow-up was 2.7 years.
The primary endpoint of 1-year non-relapse mortality (NRM) was 22.3% (95% CI, 21.2–23.5), increasing modestly to 26.7% (95% CI, 25.5–28.0) at 2 years in the total group. Corresponding 2-year overall survival (OS), progression-free survival (PFS), and relapse incidence (RI) were 54.1% (95% CI, 52.6–55.5), 48.1% (95% CI, 46.6–49.5), and 25.2% (95% CI, 23.9–26.4), respectively. Among 2,472 deaths of known cause, non-relapse causes accounted for 55%. Infection was the leading non relapse cause of death (23%), followed by GVHD (15%), and other treatment-related causes (6.8%). Incidences of grade III–IV acute GVHD and extensive/severe chronic GVHD remained low at 12.2% (95% CI, 11.3–13.1) by day 180 and 7.4% (95% CI, 6.6–8.2) at 2 years, respectively.
In multivariable analyses, patient age was not independently associated with NRM (HR per 5-year increase 1.12, 95% CI 0.97–1.30; P=0.13), OS (HR 1.12, 95% CI 1.00–1.25; P=0.055), or RI (HR 1.13, 95% CI 0.97–1.32; P=0.13), although a modest association with inferior PFS was observed (HR 1.13, 95% CI 1.02–1.26; P=0.025). Outcomes were numerically comparable between patients aged 70–74 years and ≥75 years, including 1-year NRM (22.1% vs. 24.6%), 2-year OS (54.5% vs. 49.1%), 2-year RI (25.0% vs. 26.7%), and low rates of acute and chronic GVHD in both age groups.
Instead, lower KPS (<90) (HR 1.37, 1.21-1.55; P<0.001) and HCT-CI ≥3 (HR 1.26, 1.10-1.45; P=0.001) were independently associated with higher NRM and inferior survival. NRM, OS, and PFS improved significantly over calendar time. Compared with matched related donors, both mismatched related including haploidentical donors (HR 1.75, 95% CI 1.32–2.30; P<0.001) and unrelated donors (HR 1.49, 95% CI 1.19–1.86; P<0.001) were associated with higher NRM, whereas unrelated donors had a lower relapse risk (HR 0.78, 95% CI 0.65–0.94; P=0.009). PTCy-based GVHD prophylaxis was associated with a reduced relapse risk (HR 0.75, 95% CI 0.60–0.93; P=0.009) without significant associations with NRM, OS or PFS.
CONCLUSIONS
These data demonstrate that allo-HCT is feasible in selected patients over 70 years, with >50% of patients estimated to be alive at 2 years. Age was not independently associated with NRM or OS and should not be used alone to exclude suitable patients from allo-HCT.
DISCLOSURES
Stephan Bohl, MD: Sanofi - Honoraria; Johnson & Johnson - Honoraria; Amgen - Honoraria; GSK - Honoraria; Pfizer - Honoraria; Pfizer - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)